StockDuty ← Dashboard Nov 04, 2026 10:45 AM ET
SignalCorporate

Amgen Inc (AMGN) (Q3 2026) Earnings Call Highlights: Revenue Up 8% to $10. ...

Amgen Q3 2026 revenue rose 8% to $10 billion, a key earnings catalyst.

What happened: Amgen reported Q3 2026 total revenues up 8% year over year to $10.4 billion and raised its full-year 2026 revenue and non-GAAP EPS guidance. Key numbers: Revenue $10.4 billion, up 8%. Non-GAAP operating margin 47%. Free cash flow $3.7 billion. Dividend $2.52 per share, up 6%. Why it matters: Six key growth drivers rose 27% and represented over 70% of product sales, and management said it anticipates no operating margin step-down in 2027. MariTide Phase 3 data readouts remain pending, and the regulatory path for DAZODALIBEP in Sjogren's disease remains unclear. Market: -0.9% today ($461.26), +42.8% YTD, 0.8x vol — as of 10:30 UTC Verified: Q3_2026 (Nov 3) EPS $6.45 vs $5.78 est, +11.5% beat; next print ~Feb 2 Coverage: 3 outlets in 24h
Amgen reported Q3 2026 total revenues up 8% year over year to $10.4 billion and raised its full-year 2026 revenue and non-GAAP EPS guidance.
Six key growth drivers rose 27% and represented over 70% of product sales, and management said it anticipates no operating margin step-down in 2027. MariTide Phase 3 data readouts remain pending, and the regulatory path for DAZODALIBEP in Sjogren's disease remains unclear. Market: -0.9% today ($461.26), +42.8% YTD, 0.8x vol — as of 10:30 UTC Verified: Q3_2026 (Nov 3) EPS $6.45 vs $5.78 est, +11.5% beat; next print ~Feb 2
Sources